For example, BCAT2 has been identified as a key suppressor of ferroptosis, which could inform the responsiveness to ferroptosis‐inducing therapies in HCC, CRC, and fibrosarcoma cells.[43] BCAT2 has also been implicated in forming a non‐inflammatory tumor microenvironment (TME) in bladder cancer. This evidence concerns the gene BCAT2 and urinary bladder cancer.